Postmenopausal women may reduce their risk of incident kidney stone disease by engaging in even mild physical activity and avoiding excessive caloric intake, analyses of data collected in the Women’s Health Initiative (WHI) Observational Study show.
Cheryl Guttman Krader
A new staging system for anterior urethral strictures is easy to use, demonstrates good reliability, and is expected to have useful applications in research and clinical care, say researchers from Cornell University’s Weill Medical College, New York.
Primary androgen deprivation therapy for localized prostate cancer is associated with significantly better survival outcomes in a Japanese cohort compared with an American population, according to a recent study.
New therapies that are extending survival of men with metastatic castration-resistant prostate cancer may also be contributing to an increasing trend for the development of non-osseous metastatic disease in these patients, according to a recent study.
Findings from a meta-analysis, including data from five independent patient cohorts, show that a novel genetic test is a powerful prognostic predictor of prostate cancer outcome across diverse clinical settings.
As follow-up lengthens in a prospective, randomized, controlled trial, men who underwent bipolar plasma vaporization of the prostate for BPH using the “button” vapo-resection electrode continue to demonstrate significantly better symptom scores and voiding characteristics compared to their counterparts treated by bipolar transurethral resection in saline or monopolar transurethral resection of the prostate.
In men with diabetes who are diagnosed with prostate cancer, use of metformin reduces both cancer-specific and all-cause mortality, and the treatment benefits increase with increasing cumulative duration of exposure to the drug, according to the results of a retrospective study presented at the American Society of Clinical Oncology annual meeting in Chicago.
A new AUA guideline on the early detection of prostate cancer is a PSA-focused, evidence-based guideline intended to assist the urologist in advising an average-risk, asymptomatic man about prostate cancer screening in order to reduce prostate cancer mortality, said H. Ballentine Carter, MD, at the AUA annual meeting in San Diego.
Data from a third planned interim analysis of a phase III trial are consistent with earlier results supporting the efficacy and safety of abiraterone acetate (Zytiga) as a treatment for chemotherapy-naïve men with metastatic castration-resistant prostate cancer.
For women with uncomplicated, stress-predominant incontinence, urodynamic testing adds considerable expense without improving surgical outcomes, a recent trial shows.